Medical isotope company Shine Technologies and Telix Pharmaceuticals have signed an agreement covering the supply of lutetium-177 (Lu-177) to Telix for clinical development of potential new therapeutics to treat prostate and kidney cancer.
Under the clinical supply agreement, Shine will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix's therapeutic candidates TLX591 (Lu-177 rosopatamab for advanced prostate cancer) and TLX250 (Lu-177 girentuximab for kidney cancer), according to Shine.
Isotope production will take place at Shine's facility in Fitchburg, WI. Shine is currently expanding, with a new facility under construction in Janesville, WI, near its headquarters, and a facility in the design phase in Veendam, the Netherlands.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)